“We think that this is going to be a game-changer for accelerating the high-throughput biochemical study of chromatin states and drug discovery,” said Dao. Learn more about how St. Jude researchers are using chemistry to tackle complex challenges: ow.ly/klwF50XubRB

Hai Dao, PhD, creates synthetic chromatin to enable rapid, high-throughput drug screening. Daniel Blair, PhD, streamlines analysis to synthesize thousands of compounds quickly. Tommaso Cupido, PhD, finds new ways to target dynamic enzymes.

If you are attending SfN and interested in learning more about early-career opportunities at St. Jude, visit us in Exhibit Hall B2, booth 4019, or online at stjude.org/sfn.

#SfN25

Access to specialized equipment and support empowers scientists to perform experiments at the highest caliber. The shared resources model expands opportunity, reduces barriers and drives progress toward eliminating pediatric catastrophic diseases. Learn more: ow.ly/5oGj50Xt3JS

“What really excites me about infectious disease is the medical detective work,” she said. “Thinking about our immunocompromised, oncology and transplant patients, they have unique risk factors that really play into our diagnostic approach.”

Participation in major conferences such as IDWeek and St. Jude/PIDS enables fellows to present research and engage with leaders in infectious disease. Hayley Scheerer, MD, recently presented a clinical case at ID Week and is preparing for St. Jude/PIDS in March.

AlphaSync not only updates structures as new sequences emerge, but also provides pre-computed, amino acid-level data such as interaction networks and surface accessibility, offering richer biological context for analysis.

“In a rapidly evolving scientific landscape, having access to the most current and detailed information on protein structural models is essential for breakthroughs in medicine and biology,” said M. Madan Babu, PhD, FRS.

This discovery not only clarifies the mechanism behind approved gene therapies but also reveals that targeting a specialized RNA involved in this genome structure may offer a more accessible and cost-effective treatment for patients globally.

“IHGs are often misinterpreted as incurable at presentation, but that is not true. With precise and timely management by an experienced team, these tumors can be treated successfully,” said Aditi Bagchi, MD, PhD.

Complete surgical resection followed by adjuvant therapy improves survival in IHG, but early surgery poses significant risks, especially in infants. Results highlight the need for strategies that minimize surgical morbidity while maintaining efficacy.

This approach addresses unique pediatric challenges and helps deliver safer, more effective therapies to children. As Anang Shelat, PhD, notes, “Interacting with clinicians helps us understand the clinical realities better, and that’s critical.”